Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prompt Panretinal Photocoagulation Versus Intravitreal Ranibizumab With Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Brief Summary: The primary objective of the protocol is to determine if visual acuity outcomes at 2 years in eyes with proliferative diabetic retinopathy (PDR) that receive anti-vascular endothelial growth factor (anti-VEGF) therapy with deferred panretinal photocoagulation (PRP) are non-inferior to those in eyes that receive standard prompt PRP therapy.

Secondary objectives include:

* Comparing other visual function outcomes (including Humphrey visual field testing and study participant self-reports of visual function) in eyes receiving anti-VEGF with deferred PRP with those in eyes receiving prompt PRP.
* Determining percent of eyes not requiring PRP when anti-VEGF is given in the absence of prompt PRP.
* Comparing safety outcomes between treatment groups.
* Comparing associated treatment and follow-up exam costs between treatment groups.


Options:
A: Arm Label: Panretinal photocoagulation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Panretinal photocoagulation | Arm Label: Bevacizumab + Panretinal Photocoagulation (PRP); Type: EXPERIMENTAL; Interventions: Procedure: Procedure: Panretinal Photocoagulation (PRP) Drug: Intravitreous injection of Bevacizumab | Intervention Type: PROCEDURE; Name: Panretinal photocoagulation; Assigned to Arm(s): Panretinal photocoagulation | Intervention Type: PROCEDURE; Name: Procedure: Panretinal Photocoagulation (PRP) Drug: Intravitreous injection of Bevacizumab; Assigned to Arm(s): Bevacizumab + Panretinal Photocoagulation (PRP)
B: Arm Label: Anti-VEGF+Deferred PRP; Type: EXPERIMENTAL; Interventions: Drug: 0.5-mg Ranibizumab, Other: Deferred panretinal photocoagulation | Arm Label: Prompt PRP; Type: ACTIVE_COMPARATOR; Interventions: Other: Prompt Panretinal Photocoagulation | Intervention Type: OTHER; Name: Prompt Panretinal Photocoagulation; Assigned to Arm(s): Prompt PRP | Intervention Type: DRUG; Name: 0.5-mg Ranibizumab; Assigned to Arm(s): Anti-VEGF+Deferred PRP | Intervention Type: OTHER; Name: Deferred panretinal photocoagulation; Assigned to Arm(s): Anti-VEGF+Deferred PRP
C: Arm Label: SS-PRP arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravitreal Ranibizumabe, Drug: panfotocoagulation (PRP) single shoot (ETDRS) | Arm Label: MS-PRP arm; Type: EXPERIMENTAL; Interventions: Drug: Intravitreal Ranibizumabe, Drug: panfotocoagulation (PASCAL) | Arm Label: IVR arm; Type: OTHER; Interventions: Drug: Intravitreal Ranibizumabe | Intervention Type: DRUG; Name: Intravitreal Ranibizumabe; Assigned to Arm(s): IVR arm, MS-PRP arm, SS-PRP arm | Intervention Type: DRUG; Name: panfotocoagulation (PASCAL); Assigned to Arm(s): MS-PRP arm | Intervention Type: DRUG; Name: panfotocoagulation (PRP) single shoot (ETDRS); Assigned to Arm(s): SS-PRP arm
D: Arm Label: Arm A: 0.3 mg Ranibizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab | Arm Label: Arm B: 1.5 mg Faricimab; Type: EXPERIMENTAL; Interventions: Drug: Faricimab | Arm Label: Arm C: 6 mg Faricimab; Type: EXPERIMENTAL; Interventions: Drug: Faricimab | Intervention Type: DRUG; Name: Faricimab; Assigned to Arm(s): Arm B: 1.5 mg Faricimab, Arm C: 6 mg Faricimab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Arm A: 0.3 mg Ranibizumab

Answer: B